GBA mutations, glucosylceramide and Parkinson's disease
- 1 February 2022
- journal article
- research article
- Published by Elsevier in Current Opinion in Neurobiology
- Vol. 72, 148-154
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease PatientsPLOS ONE, 2013
- Glucocerebrosidase deficiency in substantia nigra of parkinson disease brainsAnnals of Neurology, 2012
- MALDI Imaging of Lipid Biochemistry in Tissues by Mass SpectrometryChemical Reviews, 2011
- Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's diseaseMolecular Genetics and Metabolism, 2011
- The risk of Parkinson's disease in type 1 Gaucher diseaseJournal of Inherited Metabolic Disease, 2010
- Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's DiseaseNew England Journal of Medicine, 2009
- Lysosomal degradation of membrane lipidsFEBS Letters, 2009
- Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunctionActa Neuropathologica, 2009
- Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's diseaseBrain, 2009
- Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1993